Epizyme, Inc. EPZM
We take great care to ensure that the data presented and summarized in this overview for Epizyme, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Latest Institutional Activity in EPZM
Top Purchases
Top Sells
About EPZM
Insider Transactions at EPZM
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Aug 12
2022
|
Michael F Giordano Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
17,054
-73.63%
|
-
|
|
Aug 12
2022
|
Carl Goldfischer Director |
SELL
Sale (or disposition) back to the issuer
|
Indirect |
3,380,951
-100.0%
|
-
|
|
Aug 12
2022
|
Carl Goldfischer Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
22,054
-79.61%
|
-
|
|
Aug 12
2022
|
Victoria Richon Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
22,608
-80.11%
|
-
|
|
Aug 12
2022
|
David M Mott Director |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Indirect |
106,959
-100.0%
|
-
|
|
Aug 12
2022
|
David M Mott Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
8,994
-100.0%
|
-
|
|
Aug 12
2022
|
David M Mott Director |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
215,494
-95.99%
|
-
|
|
Aug 12
2022
|
Legorreta Pablo G. Director |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Indirect |
31,933,334
-100.0%
|
-
|
|
Aug 12
2022
|
Jeffery Kutok Chief Scientific Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
120,067
-66.26%
|
-
|
|
Aug 12
2022
|
Carol Stuckley Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
25,696
-100.0%
|
-
|
|
Aug 12
2022
|
Kevin T Conroy Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
62,318
-92.78%
|
-
|
|
Aug 12
2022
|
Grant C. Bogle President and CEO |
SELL
Sale (or disposition) back to the issuer
|
Direct |
259,170
-66.24%
|
-
|
|
Aug 12
2022
|
Joseph Beaulieu Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
52,076
-78.98%
|
-
|
|
Aug 12
2022
|
Beveridge, Roy A Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
46,037
-72.09%
|
-
|
|
Aug 12
2022
|
Kenneth Bate Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
17,054
-73.63%
|
-
|
|
Aug 12
2022
|
Shefali Agarwal |
SELL
Sale (or disposition) back to the issuer
|
Direct |
286,539
-81.28%
|
-
|
|
Aug 09
2022
|
Jeffery Kutok Chief Scientific Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
354,496
-74.7%
|
$354,496
$1.39 P/Share
|
|
Aug 09
2022
|
Jeffery Kutok Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
380,000
+44.47%
|
$380,000
$1.39 P/Share
|
|
Aug 09
2022
|
Grant C. Bogle President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
1,141,390
-68.15%
|
$1,141,390
$1.4 P/Share
|
|
Aug 09
2022
|
Grant C. Bogle President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
1,217,500
+41.91%
|
$1,217,500
$1.4 P/Share
|
Last 12 Months Summary
Buy / Acquisition
0
Shares
From
0
Insiders
Sell / Disposition
0
Shares
From
0
Insiders